Navigation Links
Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
Date:3/13/2008

SAN DIEGO, March 13 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to provide an overview of the company, including its clinical development and discovery programs, at two upcoming investor conferences:

-- Cowen 28th Annual Health Care Conference

Presentation: Wednesday, March 19, 2008 at 8:45 a.m. Eastern Time (5:45

a.m. Pacific Time) at the Boston Marriott Copley Place in Boston,

Massachusetts

Presenting: Jack Lief, Arena's President and Chief Executive Officer

-- Lehman Brothers Eleventh Annual Global Healthcare Conference

Presentation: Thursday, March 20, 2008 at 10:45 a.m. Eastern Time (7:45

a.m. Pacific Time) at the Loews Miami Beach Hotel in Miami, Florida

Presenting: Robert E. Hoffman, Arena's Vice President, Finance and

Chief Financial Officer

A live audio webcast of each presentation will be available under the investor relations section of Arena's website at http://www.arenapharm.com. A replay of each presentation will be available for 30 days following the event. Please connect to Arena's website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary.

About Arena Pharmaceuticals

Arena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena's most advanced drug candidate, lorcaserin, is being investigated in a Phase 3 clinical trial program for the treatment of
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Arena Pharmaceuticals to Present at the Bear Stearns 20th Annual Healthcare Conference
2. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
3. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
4. Arena Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index
5. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Arena Pharmaceuticals to Report Third Quarter 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, October 17, 2007
7. Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results
8. Arena Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Arena Pharmaceuticals Appoints Phillip M. Schneider and Randall E. Woods to Board of Directors
10. Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
11. Arena Pharmaceuticals Enters Into Strategic Agreements for the Manufacture of Pharmaceutical Material, Including Lorcaserin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... 2013 Recognizing exciting and innovative ... to its 2013 Class of Young Professors. ... provide this outstanding international group with more than ... science to meet global challenges.     , The DuPont ... young and untenured research faculty working in areas ...
(Date:5/19/2013)... May 19, 2013 Switzerland’s MS ... announced a new speed record for a transatlantic crossing ... Palmas, Spain, on April 25, 2013, the solar powered ... at the average speed of 5.3 knots before reaching ... May 18, 2013. The first-of-its-kind catamaran completed this year’s ...
(Date:5/17/2013)... Organ transplant rejection occurs when the transplant recipient,s immune ... attacks it. It was previously thought that T cells, ... activated by molecules known as chemokines in order to ... the Journal of Clinical Investigation , Fadi Lakkis ... to demonstrate that chemokine stimulation of T cells is ...
(Date:5/17/2013)... , May 17, 2013 ... the most innovative thought leaders of the medical ... Manufacturing East conference and expo, from June 18-20 ...      (Photo: http://photos.prnewswire.com/prnh/20130517/613829 ) , ... to deliver industry professionals practical presentations and implementable ...
Breaking Biology Technology:DuPont Celebrates Scientific Innovation by Recognizing Young Professors 2DuPont Celebrates Scientific Innovation by Recognizing Young Professors 3MS Tûranor PlanetSolar Sets World Speed Record for Transatlantic Crossing by Solar Electric Vessel 2MS Tûranor PlanetSolar Sets World Speed Record for Transatlantic Crossing by Solar Electric Vessel 3MS Tûranor PlanetSolar Sets World Speed Record for Transatlantic Crossing by Solar Electric Vessel 4MS Tûranor PlanetSolar Sets World Speed Record for Transatlantic Crossing by Solar Electric Vessel 5MS Tûranor PlanetSolar Sets World Speed Record for Transatlantic Crossing by Solar Electric Vessel 6MedTech Innovate Seminars: New Interactive Learning Forums at 2013 MD&M East 2
... ... Safety Solutions Continues to Accelerate., , ... (PRWEB) June 22, 2010 -- iCardiac Technologies, Inc. , a ... top 20 pharmaceutical companies have recently selected iCardiac as a preferred vendor. iCardiac ...
... 21 A global research team led by scientists ... new study in the Proceedings of the National Academy of ... genome. Lead author, Ewen Kirkness , Ph.D., JCVI, directed ... of the genome was then conducted by a large international ...
... 21 Dyadic International, Inc. (Pink Sheets: DYAI), ... addresses the needs of the multi-billion dollar biofuels market ... biomass into ethanol and other forms of alternative energy, ... firm, The Abraham Group, to provide strategic advice and ...
Cached Biology Technology:Three Top 20 Pharmaceutical Companies Select iCardiac as Preferred Vendor 2Multinational Research Team Led by J. Craig Venter Institute's Ewen Kirkness Sequence Body Louse Genome 2Multinational Research Team Led by J. Craig Venter Institute's Ewen Kirkness Sequence Body Louse Genome 3Dyadic International Engages The Abraham Group as Strategic Advisor 2Dyadic International Engages The Abraham Group as Strategic Advisor 3Dyadic International Engages The Abraham Group as Strategic Advisor 4
(Date:5/17/2013)... day, insects provide the white noise of the South, but ... year, the Southern air hangs heavy from the humidity and ... more than 140 species of frogs, toads and salamanders, is ... the ponds and swamps are the auditorium for their symphonic ... and Monitoring Initiative, or ARMI, have front-row seats. ...
(Date:5/17/2013)... all ages will celebrate the science and technology ... daily lives during the inaugural Atlanta Science Festival, ... from local museums, corporations, K-12 schools and universities, ... events for children and adults at venues across ... , The annual Atlanta Science Festival is ...
(Date:5/17/2013)... Shenzhen, China---- Why Tibetan antelope can live at ... a collaborative research published in Nature Communications ... institutes provide evidence that some genetic factors may ... highland environments. The data in this work will ... and the biology of other ruminant species. , ...
Breaking Biology News(10 mins):Front-row seats to climate change 2Front-row seats to climate change 3Front-row seats to climate change 4First Atlanta Science Festival set for 2014 2The genome sequence of Tibetan antelope sheds new light on high-altitude adaptation 2
... gibbons, arboreal primates that inhabit the jungles of Southeast Asia, ... in the genomes of all other primates, including humans. This ... approximately 25 million years ago. Their results are reported ... Research . , Agouti signaling protein ( ASIP ) was ...
... two novel genes within the tumors of women with early ... and are not at risk for early relapse or cancer-related ... April 1 issue of Clinical Cancer Research. , "The HOXB13 ... marker of relapse in hormone-receptor positive breast cancer treated with ...
... cancer-causing virus that was thought to be unimportant for its ... initiate an infection and to reproduce. , The study ... a protein it makes called p13. The protein is one ... done in laboratory-grown cells suggested that the virus could live ...
Cached Biology News:Major obesity gene is 'lost in the shuffle' 2Mayo Clinic study finds two genes predict outcome for breast cancer patients 2Cancer virus protein needed for successful infection 2
ICC Diluent Buffer 250 ml...
This antibody is specific for human J-chain as defined by ELISA assay using purified human immunoglobulin fragments as solid phase target antigen....
...
Tissue-Stat ( Tissue Adherent for Mounting Formalin-Fixed and Frozen Tissue Sections.)...
Biology Products: